Target intelligence / Profile preview

La ribonucleoprotein domain family member 6 (LARP6) mRNA (LARP6 mRNA)

Target
LARP6 mRNA
Molecular classification
Messenger RNA, RNA-binding protein transcript
01

Overview

La ribonucleoprotein domain family member 6 (LARP6) mRNA is the transcript encoding the LARP6 protein, which acts as a critical regulator of type I and type III collagen synthesis (UniProt Q9BRX2). The LARP6 protein specifically binds to a conserved 5' stem-loop (5'SL) structure in the 5' untranslated region of collagen mRNAs, a process essential for their coordinated translation and the subsequent secretion of collagen fibrils (Stefanovic, B., 2013, PubMed 19106096). In various fibrotic conditions, including liver cirrhosis, pulmonary fibrosis, and systemic sclerosis, LARP6 expression is significantly upregulated, leading to the excessive deposition of extracellular matrix (PubMed 26451368). Therapeutic targeting of LARP6 mRNA using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) aims to reduce LARP6 protein levels, thereby selectively inhibiting the production of fibrillar collagens without affecting other cellular processes. This strategy is currently being explored in preclinical models as a highly specific approach to treating fibrosis, though no such therapies have yet reached clinical approval. Potential challenges include ensuring targeted delivery to fibrotic tissues and avoiding the disruption of essential physiological collagen maintenance and wound healing.

Other names
ACHN mRNALa-related protein 6 mRNALARP6 transcript
02

Mechanism of action

Antisense-mediated degradation or RNA interference-mediated cleavage of the LARP6 transcript to prevent the translation of LARP6 protein, thereby disrupting the coordinated synthesis of fibrillar collagens.

03

Biological functions

Regulation of collagen translationFibrogenesismRNA stability
04

Disease associations

Liver fibrosisPulmonary fibrosisSystemic sclerosisCancer metastasis
05

Safety considerations

Impairment of normal wound healingPotential off-target effects on other LARP family membersSystemic collagen deficiency
06

Interacting drugs

siRNA against LARP6 (experimental)

1 more in the full profile.

07

Biomarkers

LARP6 mRNA expressionType I collagen levelsPro-collagen type I N-terminal propeptide (PINP)

Beyond the preview

Go deeper on La ribonucleoprotein domain family member 6 (LARP6) mRNA (LARP6 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on La ribonucleoprotein domain family member 6 (LARP6) mRNA (LARP6 mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call